BIOMARKER:

AR overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

AR overexpression	Triple Negative Breast Cancer	AR overexpression	Triple Negative Breast Cancer	TAK 700 Sensitive: C3 – Early Trials TAK 700 Sensitive : C3	TAK 700 Sensitive: C3 – Early Trials TAK 700 Sensitive : C3
AR overexpression	Prostate Cancer	AR overexpression	Prostate Cancer	enzalutamide capsule Sensitive: C3 – Early Trials enzalutamide capsule Sensitive : C3	enzalutamide capsule Sensitive: C3 – Early Trials enzalutamide capsule Sensitive : C3
AR overexpression	Triple Negative Breast Cancer	AR overexpression	Triple Negative Breast Cancer	enzalutamide capsule Sensitive: C3 – Early Trials enzalutamide capsule Sensitive : C3	enzalutamide capsule Sensitive: C3 – Early Trials enzalutamide capsule Sensitive : C3
AR overexpression	Breast Cancer	AR overexpression	Breast Cancer	paclitaxel Sensitive: C3 – Early Trials paclitaxel Sensitive : C3	paclitaxel Sensitive: C3 – Early Trials paclitaxel Sensitive : C3
AR overexpression	HER2 Positive Breast Cancer	AR overexpression	HER2 Positive Breast Cancer	TCHP Sensitive: C3 – Early Trials TCHP Sensitive : C3	TCHP Sensitive: C3 – Early Trials TCHP Sensitive : C3
AR overexpression	Estrogen Receptor Positive Breast Cancer	AR overexpression	Estrogen Receptor Positive Breast Cancer	RAD140 Sensitive: D – Preclinical RAD140 Sensitive : D	RAD140 Sensitive: D – Preclinical RAD140 Sensitive : D
AR overexpression	Prostate Cancer	AR overexpression	Prostate Cancer	BMS-641988 Resistant: D – Preclinical BMS-641988 Resistant : D	BMS-641988 Resistant: D – Preclinical BMS-641988 Resistant : D